Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.45 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.42 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.42 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.42 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227218 | 0.98 | NCF1 (0.47) | NCF1MAPTCYP1A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL5450935 | 0.87 | NSD2 (0.54) | MAPTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL1133969 | 0.85 | NSD2 (0.55) | MAPTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL7310592 | 0.83 | KDM4E (0.54) | NCF1MAPTCYP1A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL30819457 | 0.83 | KDM4E (0.54) | NCF1MAPTCYP1A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7308263 | 0.83 | KDM4E (0.54) | NCF1MAPTCYP1A2NPC1RAB9A | |
| SCHEMBL23193358 | 0.82 | NCF1 (0.50) | NCF1MAPTCYP1A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4381713 | 0.81 | KDM4E (0.56) | NCF1MAPTCYP1A2NPC1RAB9A | |
| SCHEMBL228713 | 0.81 | KDM4E (0.56) | NCF1MAPTCYP1A2NPC1RAB9A | |
| SCHEMBL29375172 | 0.81 | KDM4E (0.56) | NCF1MAPTCYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804859-B1 | NOVEL FAP INHIBITORS | UNIV ANTWERPEN (BE) | 2019-06-12 | — | — | EP | disclosed |
| US-9346814-B2 | FAP inhibitors | Universiteit Antwerp (BE) | 2016-05-24 | — | — | US | disclosed |
| US-20140357650-A1 | NOVEL FAP INHIBITORS | FOX CHASE CANCER CENTER (US) | 2014-12-04 | — | — | US | disclosed |
| EP-2804859-A1 | NOVEL FAP INHIBITORS | Universiteit Antwerpen (BE) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013107820-A1 | NOVEL FAP INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2013-07-25 | — | — | WO | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| CN-101535258-B | ether derivatives dual modulators of the 5HT2A and D3 receptors | HOFFMANN LA ROCHE | 2012-12-05 | — | — | CN | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| CN-1066445-C | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 2001-05-30 | — | — | CN | disclosed |
| US-5965562-A | TREATING DISORDERS INDUCED BY SUBSTANCE P AND MIGRAINE HEADACHE | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| CN-1133839-A | Aroyl-piperidine derivatives | CIBA GEIGY AG (CH) | 1996-10-23 | — | — | CN | disclosed |
| US-5541187-A | HYPOTENSIVE AGENTS | STERLING WINTHROP INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995011895-A1 | N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS | CIBA-GEIGY AG (CH) | 1995-05-04 | — | — | WO | disclosed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | GAA 4680/4885HDAC3 996/4885HDAC1 1730/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | GAA 4680/4885HDAC3 996/4885HDAC1 1730/4885 |
| US-20140357650-A1 | NOVEL FAP INHIBITORS | FAP, APC, FIBP | GAA 81/4885HDAC3 2986/4885HDAC1 1041/4885 |
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | GAA 1092/4885HDAC3 316/4885HDAC1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.